Skip to main content

Table 3 Cost-effectiveness of ECT and esketamine maintenance model with M-ECT - base case and sensitivity analysis

From: Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression

 

ECT

Esketamine

Incremental

ICER

Cost

QALY

Cost

QALY

Cost

QALY

Base case

 Societal perspective

525,707

16.83

456,219

14.26

69,488

2.57

27,070

 Healthcare perspective

220,303

16.83

120,392

14.26

99,911

2.57

38,922

Sensitivity analysis

 (1a) Doubling the productivity loss

736,918

16.83

688,314

14.26

48,604

2.57

18,935

 (1b) Halving the productivity loss

420,102

16.83

340,172

14.26

79,930

2.57

31,138

 (2a) ECT six times per cycle during depression – societal

522,167

16.83

456,219

14.26

65,948

2.57

25,691

 (2b) ECT six times per cycle during depression – healthcare

216,879

16.83

120,392

14.26

96,487

2.57

37,588

 (2c) ECT 12 times per cycle during depression – societal

532,787

16.83

456,219

14.26

76,568

2.57

29,828

 (2d) ECT 12 times per cycle during depression – healthcare

227,152

16.83

120,392

14.26

106,760

2.57

41,590

 (3a) Increasing the remission rate from esketamine to 0.5 – societal

525,707

16.83

458,462

14.36

67,245

2.46

27,290

 (3b) Increasing the remission rate from esketamine to 0.5 – healthcare

220,303

16.83

123,587

14.36

96,717

2.46

39,250

 (4a) Decreasing the remission rate from ECT to 0.5 – societal

490,004

15.54

456,219

14.26

33,784

1.28

26,326

 (4b) Decreasing the remission rate from ECT to 0.5 – healthcare

164,091

15.54

120,392

14.26

43,699

1.28

34,052

 (5a) Increasing the remission rate the 2nd time the individuals received ECT/esketamine 0.9 – societal

595,181

18.89

472,830

15.08

122,351

3.82

32,059

 (5b) Increasing the remission rate the 2nd time the individuals received ECT/esketamine 0.9 – healthcare

332,551

18.89

148,080

15.08

184,471

3.82

48,336

 (6a) Five-year time horizon – societal

127,153

3.21

116,088

2.81

11,066

0.4

27,570

 (6b) Five-year time horizon – healthcare

65,956

3.21

31,285

2.81

34,671

0.4

86,383

 (7a) Lowering QALYs (0.3) for ECT treatment during depression and increasing QALYs (0.85) for remission after esketamine and AD – societal

525,707

16.99

456,219

14.55

69,488

2.45

28,378

 (7b) Lowering QALYs (0.3) for ECT treatment during depression and increasing QALYs

    (0.85) for remission after esketamine and AD – healthcare

220,303

16.99

120,392

14.55

99,911

2.45

40,802

 (8a) Esketamine was given as long as the individual was in remission – societal

525,707

16.83

424,948

14.41

100,759

2.42

41,660

 (8b) Esketamine was given as long as the individual was in remission – healthcare

220,303

16.83

124,358

14.41

95,945

2.42

39,670

 (9a) No discounting applied – societal

540,562

17.22

469,612

14.60

70,950

2.42

27,063

 (9b) No discounting applied – healthcare

227,209

17.22

123,193

14.60

104,016

2.42

39,676

  1. Costs are displayed in British pounds (GBP) 2019
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us